Monte Rosa Therapeutics, Inc. Shareholders' Equity
Monte Rosa Therapeutics, Inc. (GLUE) had Shareholders' Equity of $487.28 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $487.28M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $521.92M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $233.06M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $245.84M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $487.28M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $521.92M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $233.06M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $245.84M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $268.08M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $275.16M 10-Q · filed 2026-08-06 |
| 2024-12-31 | $222.94M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $205.46M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $224.67M 10-Q · filed 2025-11-06 |
| 2024-03-31 | $152.52M 10-Q · filed 2025-11-06 |
| 2023-12-31 | $179.25M 10-K · filed 2026-03-17 |
| 2023-09-30 | $184.52M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $213.65M 10-Q · filed 2024-11-07 |
| 2023-03-31 | $243.73M 10-Q · filed 2024-11-07 |
| 2022-12-31 | $271.41M 10-K · filed 2025-03-20 |
| 2022-09-30 | $291.09M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $302.05M 10-Q · filed 2023-11-09 |
| 2022-03-31 | $325.88M 10-Q · filed 2023-11-09 |
| 2021-12-31 | $347.51M 10-K · filed 2024-03-14 |
| 2021-09-30 | $369.31M 10-Q · filed 2022-11-10 |
| 2021-06-30 | $356.68M 10-Q · filed 2022-11-10 |
| 2021-03-31 | -$60.62M 10-Q · filed 2022-11-10 |
| 2020-12-31 | -$48.73M 10-K · filed 2023-03-16 |
| 2020-09-30 | -$28.22M 10-Q · filed 2021-11-10 |
| 2020-06-30 | -$21.71M 10-Q · filed 2021-11-10 |
| 2020-03-31 | -$16.44M 10-Q · filed 2021-11-10 |
| 2019-12-31 | -$12.15M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |